CoChat

Interactions between chronic liver disease and inflammatory bowel disease

Open access
Loftus, Edward V., Sandborn, William J., Lindor, Keith D., Larusso, Nicholas F. · 1997 · Inflammatory Bowel Diseases
Cited by 81

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Liver disease was first recognized in association with idiopathic inflammatory bowel disease (IBD) over a century ago (1). The introduction of better diagnostic tools such as colonoscopy and endoscopic retrograde cholangiopancreatography during the last 25 years has strengthened the association between IBD and chronic hepatobiliary dysfunction, especially primary sclerosing cholangitis (PSC). IBD [ulcerative colitis (UC) and Crohn's disease (CD)] and PSC are both chronic conditions that can result in substantial morbidity and mortality and require coordinated medical and surgical interventions (2,–7). Since the conditions frequently coexist and the presence of one can alter the natural history or the management of the other, the study of the interaction between these illnesses is of great importance. We review the epidemiology, clinical features, treatment, and prognosis of hepatobiliary diseases associated with IBD as well as the unique clinical features of IBD associated with PSC. Hepatobiliary disease, once thought to be a rare extraintestinal manifestation of UC and CD, has become increasingly recognized in recent decades (3,–9). Measurement of the true prevalence of liver dysfunction in IBD remains unclear because of imprecise definitions, differences in diagnostic aggressiveness, and differences in IBD cohorts studied. For example, if “hepatobiliary disease” is defined as a single abnormal hepatic biochemical parameter, even if transiently elevated, the prevalence of “hepatobiliary disease associated with IBD” may be higher than 50%. On the other hand, persistently elevated hepatic biochemistries are less common, ranging from 3 to 50%, with an average of 12%, across numerous studies (10,–23) (Table 1). Estimates from population-based studies, which theoretically better represent the true spectrum of a given illness, range from 5 to 16% (11,13,–14,19,20,23), whereas studies from referral centers provide higher estimates (10,12,15,16). Several series detected a high prevalence of histologic hepatobiliary abnormalities in consecutive IBD patients undergoing intestinal resection; however, such series are prone to selection bias in that only patients with IBD severe enough to warrant resection are being studied (18,–22). Moreover, transient hepatobiliary abnormalities that seemingly have no impact on long-term prognosis have been noted in IBD patients during flares of acute colitis (19), and some of the pathologic findings in the surgical series may be the histologic correlates of such colitis-related rises in hepatic biochemistries. In summary, population-based estimates of the prevalence of hepatobiliary dysfunction of 4.5-15.6% likely represent minimal estimates, whereas studies of operative liver biopsies are likely to provide maximal estimates of prevalence. Prevalence of hepatobiliary disease and primary sclerosing cholangitis (PSC) in inflammatory bowel disease (IBD) Prevalence of hepatobiliary disease and primary sclerosing cholangitis (PSC) in inflammatory bowel disease (IBD) The most common hepatobiliary complications of IBD, in order of frequency and importance, are PSC, small duct PSC (“pericholangitis”), cholangiocarcinoma (carcinoma of the bile ducts), fatty infiltration of the liver, cholelithiasis, autoimmune hepatitis, and primary biliary cirrhosis (PBC). PSC is a chronic, cholestatic liver disease characterized by inflammation and fibrosis of the bile ducts (3,–7). This idiopathic disorder, with features of immune and genetic derangements, is strongly associated with IBD, especially UC, and may progress to biliary cirrhosis and hepatic failure. The only effective treatment at present is orthotopic liver transplantation (OLT) (24,25). The prevalence of PSC among patients with UC ranges from 2 to 26% (10,–23) (Table 1). Again, the wide variance in prevalence figures can be explained by definitions for both PSC and IBD, diagnostic aggressiveness, and the nature of the UC cohort studied. For example, the 26% prevalence of PSC among hospitalized UC patients at the Rikshospitalet in Oslo, Norway, between 1986 and 1991 is likely due to the fact that this facility is a national referral center for hepatology (17). Population-based studies from Scandinavia are fairly consistent in their estimates; between 2 and 7.6% of UC patients develop PSC (13,14,19,20,23). In general, the prevalence of PSC in patients with CD is much lower (˜1%), although a recent Finnish study is a notable exception (23). Owing to the extreme rarity of disease, very few direct population-based measurements of PSC prevalence have been performed. In Spain, where the prevalence of IBD is much less than that in the United States, a multicenter group estimated a prevalence of 2.24 cases of PSC per 10 × 106 persons in 1988 (26). A multicenter Swedish study measured a prevalence of PSC of 3.7% of UC patients in an area where the prevalence of UC was 170 cases per 100,000 persons in 1988, yielding a rough prevalence of 5 cases of PSC

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ibd.3780030408

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 81

Metadata

Authors
Loftus, E. V., Sandborn, W. J., Lindor, K. D., & Larusso, N. F.
Venue
Inflammatory Bowel Diseases
Published
1997
Volume
3
Issue
4
Pages
288-302
ISSN
  • 1078-0998 (ISSN-L)
  • 1536-4844
OpenAlex
W2082412444
Cited by
81
References
9
FWCI
0.20
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.